265 related articles for article (PubMed ID: 38259475)
1. Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream.
Calabrò L; Bronte G; Grosso F; Cerbone L; Delmonte A; Nicolini F; Mazza M; Di Giacomo AM; Covre A; Lofiego MF; Crinò L; Maio M
Front Immunol; 2023; 14():1333661. PubMed ID: 38259475
[TBL] [Abstract][Full Text] [Related]
2. What's Current and What's New in Mesothelioma?
Leal JL; Hoang W; Xue J; Dunne B; John T; Harden S
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):771-780. PubMed ID: 36155156
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Zeng X; Jiang Z; Duan J
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
[TBL] [Abstract][Full Text] [Related]
4. Unprecedented long-term survival in a patient with malignant pleural mesothelioma treated with subsequent systemic chemo- and immunotherapeutic regimens.
Cerbone L; Delfanti S; De Angelis AM; Crivellari S; Boccuzzi F; Cimorelli A; Bertolotti M; Righi L; Bertino P; Grosso F
Thorac Cancer; 2023 Feb; 14(5):524-527. PubMed ID: 36599413
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
6. Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.
Dubois F; Bazille C; Levallet J; Maille E; Brosseau S; Madelaine J; Bergot E; Zalcman G; Levallet G
Target Oncol; 2022 Jul; 17(4):407-431. PubMed ID: 35906513
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
8. Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
Tagliamento M; Di Maio M; Remon J; Bironzo P; Genova C; Facchinetti F; Aldea M; Le Péchoux C; Novello S; Barlesi F; Besse B; Planchard D
J Thorac Oncol; 2024 Jan; 19(1):166-172. PubMed ID: 37567387
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
[TBL] [Abstract][Full Text] [Related]
10. [Advances in Immunotherapy for Malignant Pleural Mesothelioma].
Chi Y; Liu Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):259-265. PubMed ID: 35477190
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor therapy for malignant pleural mesothelioma.
Nowak AK; Chin WL; Keam S; Cook A
Lung Cancer; 2021 Dec; 162():162-168. PubMed ID: 34823106
[TBL] [Abstract][Full Text] [Related]
12. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
[TBL] [Abstract][Full Text] [Related]
13. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.
Perera ND; Mansfield AS
Curr Oncol Rep; 2022 Nov; 24(11):1413-1423. PubMed ID: 35657483
[TBL] [Abstract][Full Text] [Related]
15. Novel therapies for malignant pleural mesothelioma.
Scherpereel A; Wallyn F; Albelda SM; Munck C
Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
[TBL] [Abstract][Full Text] [Related]
16. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
17. Improvements in Systemic Therapies for Advanced Malignant Mesothelioma.
Deiana C; Fabbri F; Tavolari S; Palloni A; Brandi G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445594
[TBL] [Abstract][Full Text] [Related]
18. Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.
Hu ZI; Ghafoor A; Sengupta M; Hassan R
Cancer; 2021 Apr; 127(7):1010-1020. PubMed ID: 33620732
[TBL] [Abstract][Full Text] [Related]
19. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
Remon J; Reguart N; Corral J; Lianes P
Cancer Treat Rev; 2015 Jan; 41(1):27-34. PubMed ID: 25467107
[TBL] [Abstract][Full Text] [Related]
20. Management of Advanced Pleural Mesothelioma-At the Crossroads.
Nowak AK; Jackson A; Sidhu C
JCO Oncol Pract; 2022 Feb; 18(2):116-124. PubMed ID: 34491782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]